{"id":5755,"date":"2025-12-01T10:31:41","date_gmt":"2025-12-01T09:31:41","guid":{"rendered":"https:\/\/www.probeltepharma.es\/2025\/12\/01\/probelte-pharma-published-the-protocol-for-the-proacaros-phase-iii-beltavac-clinical-trial-in-the-trials-journal\/"},"modified":"2026-03-04T11:09:56","modified_gmt":"2026-03-04T10:09:56","slug":"probelte-pharma-published-the-protocol-for-the-proacaros-phase-iii-beltavac-clinical-trial-in-the-trials-journal","status":"publish","type":"post","link":"https:\/\/probeltepharma.es\/en\/2025\/12\/01\/probelte-pharma-published-the-protocol-for-the-proacaros-phase-iii-beltavac-clinical-trial-in-the-trials-journal\/","title":{"rendered":"Probelte Pharma published the protocol for the PROACAROS phase III Beltavac\u00ae clinical trial in the TRIALS journal"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text uncode_shortcode_id=”821874″]Murcia, Spain \u2014 May 2025<\/strong><\/p>\n

Probelte Pharma has announced that the full protocol for the PROACAROS<\/strong> phase III clinical trial, designed to evaluate the efficacy and safety of Beltavac\u00ae<\/strong> subcutaneous immunotherapy in patients with house dust mite allergic rhinitis, has been published in the prestigious scientific journal TRIALS<\/strong>.<\/p>\n

By publishing this article, Probelte Pharma has become the first and only company in the allergen immunotherapy industry<\/strong> to publicly and transparently share the detailed methodology of a clinical trial of this kind. This milestone underscores the company’s commitment to scientific excellence<\/strong>, regulatory innovation<\/strong>, and further developing precision treatments for allergic patients<\/strong>.<\/p>\n

This article has brought key added value for the scientific and regulatory defence of the project by aligning with the guidelines of the European Medicines Agency (EMA)<\/strong> and the European Academy of Allergy and Clinical Immunology (EAACI)<\/strong>. Furthermore, the protocol included technological tools specifically designed<\/strong> to support digital patient monitoring and the real-time assessment of clinical outcomes, thus building a more agile, robust and patient-centred research model.<\/p>\n

The publication of the PROACAROS trial cemented Probelte Pharma’s role as a leading source of high-quality scientific evidence and underlined its strong commitment to the future of allergen immunotherapy.<\/p>\n

View the full article here:<\/strong><\/p>\n

https:\/\/rdcu.be\/eoj26<\/a>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_column_text uncode_shortcode_id=”821874″]Murcia, Spain \u2014 May 2025 Probelte Pharma has announced that the full protocol for the PROACAROS phase III clinical […]<\/p>\n","protected":false},"author":13,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[967],"tags":[],"class_list":["post-5755","post","type-post","status-publish","format-standard","hentry","category-research-and-development"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t